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Abstract
Background: Human uterine leiomyomas (ULM) are characterized by dysregulation of a large number of genes and non-
coding regulatory microRNAs. In order to identify microRNA::mRNA associations relevant to ULM pathogenesis, we
examined global correlation patterns between the altered microRNA expression and the predicted target genes in ULMs
and matched myometria.
Methodology/Principal Findings: Patterns of inverse association of microRNA with mRNA expression in ULMs revealed an
involvement of multiple candidate pathways, including extensive transcriptional reprogramming, cell proliferation control,
MAP kinase, TGF-b, WNT, JAK/STAT signaling, remodeling of cell adhesion, and cell-cell and cell-matrix contacts. We further
examined the correlation between the expression of the selected target gene protein products and microRNAs in thirty-six
paired sets of leiomyomas and matched myometria. We found that a number of dysregulated microRNAs were inversely
correlated with their targets at the protein level. The comparative genomic hybridization (CGH) in eight ULM patients
revealed that partially shared deletions of two distinct chromosomal regions might be responsible for loss of cancer–
associated microRNA expression and could thus contribute to the ULM pathogenesis via deregulation of target mRNAs.
Last, we functionally tested the repressor effects of selected cancer-related microRNAs on their predicted target genes in
vitro.
Conclusions/Significance: We found that some but not all of the predicted and inversely correlated target genes in ULMs
can be directly regulated by microRNAs in vitro. Our findings provide a broad overview of molecular events underlying the
tumorigenesis of uterine ULMs and identify select genetic and regulatory events that alter microRNA expression and may
play important roles in ULM pathobiology by positively regulating tumor growth while maintaining the non-invasive
character of ULMs.
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Introduction
Uterine leiomyomas (ULMs) are the most common benign
smooth muscle tumors in women of reproductive age. About 40%
of ULMs contain non-random chromosomal anomalies involving
a small number of specific chromosomal regions [1]. Global gene
expression profiling of ULMs revealed that hundreds of genes are
dysregulated including those with functional roles in cell
proliferation, differentiation and extracellular matrix production
[2]. So far, only a few specific genes or cytogenetic aberrations
have been identified to be associated with ULMs. While many of
the dysregulated genes may function as either effectors or
promoters of ULMs growth, they are likely secondarily induced
and indirectly responsible for tumor growth into morbid and
symptomatic ULMs.
MicroRNAs are a class of small, non-coding regulatory RNAs.
In cells, transcribed microRNA precursors (pri-microRNAs)
undergo multistep biogenesis to form mature microRNAs of 18–
25 nucleotides in length [3]. MicroRNAs regulate a high number
of biological processes including cell proliferation, differentiation
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of particular mRNAs [4] and are aberrantly expressed in many
solid tumors [5,6,7,8,9,10] including uterine ULMs [11,12,13].
According to miRBase (Release 15), a total of 940 human
microRNAs have been identified [14]. Cloning approaches and
computational predictions have indicated that there are possibly
even more microRNA encoding loci in the human genome [15].
Largely based on ectopic expression experiments and computa-
tional algorithms for prediction of microRNA target sites in
mRNA sequences, it is estimated that each microRNA may
regulate hundreds of genes at the post-transcriptional and
translational levels [16].
Recently, studies revealed that a subset of microRNAs are
significantly dysregulated in ULMs compared to matched
myometria [11,12,13]. Many of these microRNAs are also
associated with other neoplasms, indicative of their roles in
tumorigenesis in general [13]. It is thus important to establish the
roles played by the highly dysregulated microRNAs in ULMs
pathogenesis through regulation of specific target genes with key
roles in tumorigenesis. We and others demonstrated that the let-7
microRNA family could functionally repress HMGA2 expression
[13,17,18,19]. These findings prompted us to explore the broader
relationship between other dysregulated microRNAs and their
target genes exhibiting aberrant expression in ULMs.
In this study, we compared global microRNA expression
patterns with the expression of their predicted target genes, at
both mRNA and protein levels, in paired sets of ULMs and
matched myometria, focusing primarily on the inverse association
between the levels of microRNAs dysregulated in ULMs and the
expression of their predicted target genes. We found that in uterine
ULMs the levels of the most dysregulated microRNAs show an
inverse association with the expression levels of many predicted
target genes, and that they may affect multiple homeostatic
pathways and functions. Next, by correlating comparative
genomic hybridization (CGH) results and microRNAs data, we
found that dysregulation of certain microRNAs with established
roles in cancer could be due to the underlying genomic alterations.
Finally, we show that selected predicted target genes can be
validated as functional targets of specific microRNAs in vitro.I n
summary, our study offers a catalogue of microRNA, mRNA and
protein expression alterations genetically or functionally related to
the pathogenesis of human uterine ULMs.
Materials and Methods
Patients and Tissue Samples
This study included 55 uterine ULMs of usual type from 41
patients, as published elsewhere [13]. All clinical information is
well documented. Among 55 ULMs, 36 ULMs and matched
myometria were collected to prepare high density tissue micro-
array (TMA) from formalin-fixed paraffin embedded tissue
(FFPE), and 24 ULMs and matched myometria were collected
to prepare total RNA from snap frozen tissue, and used for RT-
PCR validation. Among them, eight were selected for comparative
genomic hybridization and five cases were selected for gene
expression analysis (see below). The patient and tissue sample
information is summarized in Table 1. The study was approved by
the New York University and Northwestern University institu-
tional review boards.
Cell lines
Four uterine smooth muscle cell lines were used for the study.
They include two immortalized uterine leiomyoma cell lines,
ULM-3401 (obtained from an intramural leiomyoma of 45 year
old African American woman), immortalized by the introduction
of stable human telomere terminal transferase expression (hTERT)
and UtLM, obtained from Dr. Dixon’s lab (for details please see
reference [20]). ULM-3401 exhibits a high level of HMGA2
expression. Two uterine leiomyosarcoma cell lines SK-LMS-1 and
SK-UT-1 were obtained from ATCC.
Gene expression analysis
The mRNA expression profiles of 5 ULMs and matched
myometria were examined. AffymetrixH HG-U133A GeneChips
were used to generate expression data for 22,000 probe sets
identifying 18,400 transcripts of 14,500 genes. ULMs and
matched myometrial tissues were homogenized in lysis buffer
(Ambion, Austin, TX). Following the manufacturer’s protocol,
total RNA extraction and clean-up were performed using an
Ambion RNA purification kit (Ambion, Austin, TX). RNA
samples were processed following the Affymetrix protocol
(Affymetrix Inc., Santa Clara, CA). In brief, 8 mg of total RNA
was amplified, biotin labeled, and hybridized to the Affymetrix
HG-U133A GeneChips (Affymetrix Inc.). The gene expression
data from ULMs previously published by Hoffman et al [21]
were obtained from the NCBI Gene Expression Omnibus
database under the accession number GSE593, with sample
IDs GSM9093 through GSM 9102. This data set was used as
reference to compare with our gene profiling data. The raw array
data generated in this study are deposited in NCBI GEO
database under the identifier GSE 23112.
Comparative genomic hybridization (CGH)
Eight ULMs and matched myometria from African American
women were selected for array CGH analysis (Table 1). Genomic
DNA from ULMs were used as the ‘‘test’’ DNA and matched
myometria as the ‘‘reference’’ DNA during the hybridization
reaction. Human Genome CGH 44K Microarrays (ID:014950)
from Agilent Technologies were used according to the instructions
of the array manufacturer. Briefly, the test and reference DNAs
were digested with Alu I and Rsa I (Promega), and purified with
the QIAprep Spin Miniprep kit (Qiagen). Test DNA (500 ng) and
reference DNA (500 ng) l were labeled with either Cy3-dUTP or
Cy5-dUTP (Perkin Elmer) using the Bioprime Array CGH
Genomic Labeling kit (Invitrogen), and hybridized with 26
Hybridization buffer (Agilent, Palo Alto, CA), 106blocking agent
(Agilent,), and Human Cot-1 DNA (Invitrogen) in an Agilent
SureHyb chamber for 24 hours at 65uC. After four washing steps,
all slides were scanned by Agilent Scanner (G2565CA). Raw data
were obtained by Agilent Feature extraction software 9.0, and
then imported into Agilent CGH analytics 3.5 software for
analysis.
DNA copy number changes were detected by CGH analytics
software 3.5 (Agilent). The ADM-1 statistical algorithm was used
with a sensitivity threshold of 6.0 and a moving average window of
1 Mb. In order to determine that there was a copy number change
in a particular locus, three criteria had to be met. These were
positive calls by the software, presence of 10 consecutive probes
pointing in the same direction, and 1.5 fold average fold difference
in the test DNA compared to the reference DNA.
Expression data and bioinformatics analyses
GeneSpring GX11 (Agilent Technologies, Palo Alto, USA) and
TM4 Microarray Software Suite [22] were used to identify
differentially expressed mRNAs in ULMs. The raw array
intensities (CEL files) were normalized using robust multichip
average (RMA) and filtered using Significance Analysis of
Microarrays (SAM) with a false discovery rate of 5%. The
MicroRNAs in Uterine Leiomyoma
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were then used to identify, on the mRNAs that passed the
statistical filtering, putative targets of the 10 most highly
dysregulated microRNAs (top five up and top five down). The
genes identified by both prediction algorithms were further
analyzed by function and pathway using the Database for
Annotation, Visualization and Integrated Discovery (DAVID),
available from http://david.abcc.ncifcrf.gov/ [23]. Unsupervised
Table 1. Summary of patient and tissue sample information.
Case No. Ethnic
Age
(yrs)
Uterine weight
(gm)
Tumor size
(cm)
No. Tumors
(n) Profile TMA RT-PCR
miRNA* mRNA CGH
C4 Black 45 750 10.5 5 yes yes yes yes Yes
C7 Black 48 850 11 5 yes yes yes yes
C18 Black 48 2500 12 30 yes yes yes yes yes
C19 Black 48 3800 24 8 yes yes yes yes yes
C21 Black 43 1000 9 11 yes yes
C32 Black 35 1300 17 6 yes yes yes yes yes
C36 Black 42 1050 15 42 yes yes yes yes yes
C41 Black 51 900 9 50 yes yes yes yes
C51 Black 39 2210 14 105 yes yes yes yes
C52 Black 52 5400 26 20 yes yes yes
C56 Black 50 600 12 10 yes yes yes
C57 Black 50 1140 8 102 yes yes yes
C58 Black 50 440 6 52 yes
C59 Black 45 950 10 20 yes
C68 Black 50 840 8 10 yes
C6 White 52 1200 17 3 yes yes yes
C9 White 38 450 12 2 yes yes yes
C10 White 52 1200 11 10 yes yes** yes
C13 White 44 475 11.5 3 yes yes yes
C15 White 38 2100 14 5 yes yes yes
C20 White 46 1200 11 2 yes yes** yes
C22 White 53 1875 14 5 yes yes yes
C26 White 46 650 8 25 yes yes yes
C29 White 56 1500 11 5 yes yes yes
C46 White 51 1300 11 51 yes yes yes
C47 White 47 1150 12 15 yes yes yes
C53 White 54 2400 20 3 yes yes
C61 White 48 1200 10 10 yes yes
C66 White 45 850 11 3 yes yes
C67 White 54 650 8 3 yes
C3 Asian 44 800 7 22 yes
C24 Asian 42 890 13 2 yes yes
C27 Asian 56 950 10.5 5 yes yes
C24 Asian 40 1100 13 12 yes
C40 Asian 41 950 8 25 yes yes
C42 Asian 51 900 12 5 yes yes
C1 Hisp 41 1100 11 10 yes yes
C5 Hisp 48 550 11 6 yes yes
C14 Hisp 48 1100 14 5 yes yes
C16 Hisp 50 2100 11 40 yes yes
C23 Hisp 47 450 8.5 2 yes
*Wang et al. 2007.
**Two tumors (Large and small).
doi:10.1371/journal.pone.0012362.t001
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between microRNAs and target mRNA/protein levels. For
visualization of global microRNA::mRNA interactions in ULMs,
box plots were used as a convenient way of graphically depicting
the regulation of the mRNA targets of the 5 most highly
upregulated and 5 most downregulated microRNA. The arms of
the box plot represent the smallest and largest observation, the box
is delimited by the lower and upper quartile, and the line through
the box represents the median of the observations. Gene set
enrichment analysis (GSEA) in ULMs versus matched myometria
was performed according to the authors’ guidelines published at
the Broad Institute web pages (http://www.broadinstitute.org/
gsea/index.jsp), using C2 (curated gene sets) and C5 (Gene
Ontology gene sets) collections using Signal2Noise ratios.
MicroRNA transfection
MicroRNA oligonucleotides were used at a concentration of
60 pmol/well for a 6-well plate. To estimate transfection
efficiency, the negative control Block-iT (Fluorescent double-
stranded random 22mer RNA from Invitrogen (Carlsbad, CA))
and positive control TSC2 siRNA (Invitrogen, CA) were used.
Mature microRNAs mimics and inhibitors from let-7c and miR-296
were purchased from Dharmacon Inc. (Lafayette, CO). Cells
receiving only the tagged random sequence (Block-iT) were used
as non-specific references at all data points. Following transfection,
cells were harvested and analyzed at the indicated times.
shRNA miR-200a infection
Human miR-200a shRNA in pGIPZ was prepared. Lentivirus
expressing miR-200a shRNA were produced in HEK293T cells
packaged by pMD2G and psPAX2. For stable infection, 4610
4
cells/mL of UtLM cells were plated in each well of 6-well plates in
2 ml medium without antibiotics. After overnight incubation,
media was replaced with 1 ml Opti-MEMH I Reduced-Serum
Medium containing 12 mg/mL polybrene per well. 50 mLo f
concentrated lentiviral particles were added to each well. After
48 hours infection, fresh media was added containing 2 mg/ml
puromycin. Fresh media with puromycin was replaced every 3–4
days. Single clones were picked after two weeks of puromycin
selection. Stable miR-200a expression was validated by RT-PCR
(see below).
Cellular proliferation assay
UtLM cells were seeded in 24-well plates in triplicate wells at
densities of 1610
4 per well. Cell proliferation was monitored at 24,
48, 72 and 96 hrs using the colorimetric MTS assay (CellTiter 96H
Aqueous Assay, Promega).
Luciferase transfection assays
Cell lines were transfected with 200 ng luciferase reporter PGL-
3 control (Promega, Madison, WI), or pGL-3 HMGA2-39UTR
construct and 1ng of the pRLuc internal control plasmid
(Biosignal, Montreal, QB). The luciferase expression was deter-
mined as recommended by Promega (Madison, WI).
Western blot analysis
The culture cell samples were homogenized at 4uC in a protein
lysis buffer. Equal amounts of total protein from each sample were
resolved through a 10% SDS–PAGE gel and then transferred to a
PVDF membrane (Perkin Elmer Life Scientific Inc.). Development
of the immunoblot with antisera against TSC2 (from Dr.
Mizuguchi [24,25]) was tested and a single specific HMGA2
band at 25 kDa was detected, as previously described.
RT-PCR
For detection of mature microRNAs, mirVana qRT-PCR
Primers and the mirVana qRT-PCR Detection Kit (Ambion,
Austin, TX) were used and optimized according to the abundance
of microRNAs in the tested tissue samples. Primers for 11 let-7 and
5 miR-200 predicted target genes are summarized in Table S1.
The abundance of cDNA products was normalized to the internal
controls of small nuclear RNA U6 and a-Actin.
Tissue Microarrays, immunohistochemistry and scoring
All tissue sections were reviewed and cellular areas of tumor
were selected for TMA analysis. Six 0.6 mm tissue cores were
collected from each case, including three cores of ULMs and three
cores of matched myometria. The technical details and reliability
of the data have been described previously [26]. In brief, 432 tissue
cores from 36 ULM with matched myometria were arrayed into
one recipient paraffin block. The tissue cores were arrayed in a
random distribution of cases.
Antibodies selected for this study included sixteen protein
markers and are listed in Table S2. The detailed protocols and
conditions used for each antibody followed the manufacturers’
recommendations which were described previously [27]. In brief,
the paraffin-embedded tissue array blocks were sectioned at 4 mm.
Antigen retrieval was performed by either heat-induced epitope
retrieval or by proteolytic enzyme digestion as previously
described. All immunohistochemical staining procedures were
performed on a Ventana Nexus automated system (Tucson,
Arizona, USA).
Stained TMA slides were graded jointly by two pathologists
using a visual semiquantification method (optical density of the
immunoreactivity) depending on the staining characteristics of the
antibody. The net gain or loss of immunoscores was calculated for
a specific immunomarker from each individual ULM in
comparison with matched myometrium (net value=tumor
immunoscore 2 myometrial immunoscore). Each net value gave
positive or negative scores.
Results
Largely based on ectopic expression studies and computational
analyses, it has been predicted that microRNAs can regulate at
least 30% of gene transcripts. Several recent studies have
compared microRNA expression with the levels of corresponding
predicted target genes in normal and tumor tissues at a global
level. Our previous findings of microRNA dysregulation in ULMs
led us to further examine whether these dysregulated microRNAs
correlated with abnormal expression of their predicted target
genes at both transcriptional and translational levels.
Genome-wide correlation of dysregulated microRNAs
and their predicted mRNA targets
We had reported that a subset of 45 microRNAs were
differentially expressed between ULMs and matched myometria
[13]. To test whether altered expression of microRNAs in ULMs
are responsible for dysregulation of the predicted target gene
expression, we selected five ULMs and matched myometria (for
which we had identified microRNA profiles, see Table 1) for gene
expression analysis using Affymetrix U133A arrays. The five cases
selected for the gene expression study were marked by the most
significant microRNA dysregulation in ULMs and the highest
magnitude of their modulation (Figure S1). In particular, we
selected ULMs of large size (.10 cm) and from African American
women. As previous stated by Aslan et al [2], the gene expression
profiles in ULMs varied widely among studies, affected by the
MicroRNAs in Uterine Leiomyoma
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the NCBI GEO GSE593 ULM profiling along with the data from
this study due to the same sample size, patient age and the
microarray platform used [21].
Applying significance analysis of microarray to the combined set
of our 5 pairs of ULM and matched myometria and the GSE593
data, we identified 2674 probe sets (1,117 up- and 1,557 down-
modulated) that were significantly different between ULMs and
matched myometrium controls (Figure S1).
We used a combination of two microRNA prediction methods,
TargetScan and PicTar, to search for all predicted gene targets of
the 5 most highly upregulated (let-7s, miR-21, miR-23b, miR-27a and
miR-30a) and downregulated (miR-29b, miR-32, miR-144, miR-197
and miR-212) microRNAs [13]. Both mRNA profiling data sets
(ours and GSE593) were used for the microRNA target prediction.
There were a total of 2995 and 2060 TargetScan and PicTar-
predicted genes of the top 5 upregulated and 5 top downregulated
microRNAs, respectively (Figure 1A). Utilizing the expression data
from these five cases, we identified 2674 mRNAs that were
significantly dysregulated in ULMs (SAM, FDR,5%, Figure 1A).
Among these significantly dysregulated mRNAs, 249 downregu-
lated mRNAs were predicted targets of the 5 upregulated
microRNAs and 97 upregulated mRNAs were predicted targets
of the 5 downregulated microRNAs (Figures 1B). Together, they
represented 13% of 2674 genes found to be significantly
dysregulated in ULMs. The Box Plot analysis and significance
analysis revealed a trend of overall inverse association between the
predicted target genes and either up- or down- regulated
microRNAs (Figure 1B). Upregulated predicted gene targets of
downregulated microRNAs were significantly enriched in com-
parison to the overall pool of significantly dysregulated targets
(0.05.p.0.01). The findings suggest that the most up and down
regulated microRNAs in ULMs may regulate the expression of
their predicted target genes at the level of mRNA stability as
previously reported [28].
At the level of individual matches between microRNAs and the
inversely modulated, predicted targets, a rather small proportion
of the target genes were inversely correlated with a considerable
correlation coefficient (ranging from r=20.5 to 20.95, see
Table 2). Small sample size and important biological variables
Figure 1. Predicted target genes or microRNAs in uterine ULMs. A Predicted target genes for the 5 most highly upregulated (left) and 5 most
highly downregulated microRNAs (right). TargetScan (light blue) and PicTar (yellow) identified 1884 genes as predicted targets of the 5 most highly
upregulated microRNAs (let-7s, miR-21, miR-23b, miR-27a and miR-30a). Among 1079 significantly downregulated genes in ULMs (pink circle), 188
(intersection of the three circles) are the best predicted targets of these upregulated microRNAs. B Differential expression of the predicted target
genes for each of the 5 most highly upregulated microRNAs (B1) and downregulated microRNAs (B2) in ULMs and matched myometria. Each box plot
represents the average level of predicted target gene expression. Expression of microRNA targets is plotted as RMA-normalized, median centered and
log2-transformed, relative abundance levels (Y-axis), with a baseline=1 corresponding to median centered normal myometrial samples.
doi:10.1371/journal.pone.0012362.g001
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that levels of mature microRNAs do not necessarily reflect their
functional impact may be the reason for the decreased rates of
significant negative correlation of individual microRNA and
mRNA expression patterns.
Correlation of microRNA expression with protein
expression in pair-matched tissue samples of ULMs and
myometria
To further investigate the correlation of microRNAs and
predicted targets in ULMs, we examined the predicted target
gene products by immunohistochemistry analysis to establish the
effects of microRNAs on the synthesis of target proteins. We
utilized ULMs and matched myometria from 36 cases, from which
global microRNA expression profiles had been obtained [13]
(Table 1). A total of 16 proteins (Table S2) that were known to be
significantly dysregulated in ULMs [27,29] were selected for
immunohistochemical analysis. The relative expression level of
each protein was scored in a semiquantitative manner in ULMs
and in matched myometrial controls (see Methods). The net
changes of the selected gene products (Figure S3) were analogous
to our previously published studies in ULMs [27,29].
The Ki-67 index in ULMs in comparison to the matched
myometria can be used to evaluate tumor growth rate. Correlation
of let-7 microRNA levels in 36 ULMs established an inverse
association with the Ki-67 index (MKI67 protein expression)
(Figure 2).
Moderate individual negative correlations with microRNAs were
found for EGFR and miR-194-1, TGFa and miR-199a-2 (r=20.39
and r=20.58, respectively), however, the overall pattern appeared
entirely inversely correlated (Figure 2). Most other gene products,
the patterns of which correlated with their targeting microRNAs,
exhibited similar negative correlation (r=20.2 to 20.4) (data not
Table 2. Correlation analyses of top 10 most highly dysregulated miRNAs and their predicted target genes in 5 large ULM of black
women based on global gene expression profiles.
miRNA Symbol Target gene Name AFFY ID Correlation coefficient (n=5)
let7c TRIB1 tribbles homolog 1 (Drosophila) 202241_at 20.437
let7f-2 PLCB4 phospholipase C, beta 4 203896_s_at 20.648
miR-21 BRD1 bromodomain containing 1 215460_x_at 20.878
SKI v-ski sarcoma viral oncogene homolog (avian) 204270_at 20.435
miR-27a ANK2 ankyrin 2, neuronal 202921_s_at 20.942
RAB11FIP RAB11 family interacting protein 1 (class I) 219681_s_at 20.869
GATA2 GATA binding protein 2 209710_at 20.890
FOSB FBJ murine osteosarcoma viral oncogene homolog B 202768_at 20.662
PPARG peroxisome proliferative activated receptor, gamma 208510_s_at 20.692
miR-30a-5p SMARCD2 SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily d, member 2
201827_at 20.760
SLC29A3 solute carrier family 29 (nucleoside transporters),
member 3
219344_at 20.604
HLF hepatic leukemia factor 204755_x_at 20.817
MAP3K5 mitogen-activated protein kinase kinase kinase 5 203836_s_at 20.881
TNXA tenascin XA pseudogene 216339_s_at 20.598
miR-23b PPARG peroxisome proliferative activated receptor, gamma 208510_s_at 20.766
HIVEP2 human immunodeficiency virus type I enhancer
binding protein 2
212641_at 20.828
GATA2 GATA binding protein 2 209710_at 20.863
FOSB FBJ murine osteosarcoma viral oncogene homolog B 202768_at 20.641
miR-29b BMP1 bone morphogenetic protein 1 202701_at 20.942
RARB retinoic acid receptor, beta 205080_at 20.625
FAM131B family with sequence similarity 131, member B 205368_at 20.814
NASP nuclear autoantigenic sperm protein (histone-binding) 201969_at 20.940
TGFB3 transforming growth factor, beta 3 209747_at 20.644
miR-32 NFIB nuclear factor I/B 211467_s_at 20.785
FLI1 Friend leukemia virus integration 1 210786_s_at 20.805
FHL3 four and a half LIM domains 3 218818_at 20.799
miR-212 PRKD1 protein kinase D1 205880_at 20.308
miR-144 PTHLH parathyroid hormone-like hormone ;
parathyroid hormone-like hormone
211756_at 20.239
miR-197 RNPC1 RNA-binding region (RNP1, RRM) containing 1 212430_at 20.803
TNRC5 trinucleotide repeat containing 5 217931_at 20.566
doi:10.1371/journal.pone.0012362.t002
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correlation of microRNA and the target proteins are illustrated by inverse correlation of regulating miRNAs and their select targets. The gene
expression levels are depicted by the intensity of yellow (overexpression), white (no change) and blue (underexpression) color. In each panel,
correlated microRNAs and the target proteins are shown on the top and tumor IDs are on the right.
doi:10.1371/journal.pone.0012362.g002
Table 3. Comparative genomic hybridization analysis and associated microRNAs in eight large leiomyomas of black women.
Patient Chr. bands Size (Mb) Aberrations MiRNAs in regions of loss*
B1 3p11.2-p11.1 0.55 loss -
3q13.31-q21.2 9.90 loss miR-198
3q22.2-q27.2 49.60 loss miR-15b, miR-16-2, miR-1263, miR-720, miR-551b, miR-569, miR-1224
B2 No change - - -
B4 1p36.33-p34.3 38.66 loss miR-200b, miR-200a, miR-429, miR-551a, miR-34a, miR-1290, miR-1256, miR- 552
3q26.1-q29 37.68 loss miR-15b, miR-16-2, miR-1263,miR- 720, miR-551b,miR- 569, miR-1224,
miR-1248, miR-28, miR-944, miR-570, miR-922
6q13-q24.3 76.21 loss miR-30c-2, miR-30a, miR-2113, miR-587, miR-548b, miR-588, miR-548a-2
13q12.12-q33.2 82.49 loss miR-320d-1, miR-621, miR-16-1, miR-15a, miR-1297, miR-622,
miR-17, miR-18a, miR-19a, miR-20a, miR-19b, miR-92a-1, miR-623
B5 No change - - -
B6 No change - - -
B7 22q11.1-q13.33 35.09 loss miR-648, miR-185, miR-1306, miR-1286, miR-649, miR-301b, miR-130b,
miR-650, miR-548j, miR-658, miR-659, miR-1281, miR-33a, miR-1249, let-7a-3, let-7b
B8 No change - - -
B9 1p36.33-p36.23 7.09 loss miR-200b, miR-200a, miR-429, miR-551a
3p12.3-p11.1 10.24 loss -
6p25.3-p22.2 24.79 loss miR-548a-1
6p12.3-p11.1 11.61 loss miR-206, miR-133b
*: bold=miRNA detected as downregulated in the patient.
doi:10.1371/journal.pone.0012362.t003
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correlative analysis of inverse associations of microRNA and tumor-
associated protein expression levels.
Genomic alteration and microRNA expression
To evaluate whether selected dysregulated microRNAs in
ULMs associated with specific genomic alterations, we performed
comparative genomic hybridization (CGH). We selected 8 cases
of ULMs for the study (Table 1). By comparison to matched
myometria, few genomic alterations were found (Table 3, Figure
S2). In general, the loss of genomic material was the only finding
in all eight cases. Chromosomal regions of 1p36, 3p11, 3q22 and
6p were the most commonly altered, with 1p36.33-p36.23 and
3q26.1-q27.2 established as regions of deletion overlap between
ULMs derived from patients B4, B9 and B1, B4, respectively.
Interestingly, members of cancer-inhibitory miRNA family miR-
200a, miR-200b, miR-429 and miR-551a are located in the region
of loss at 1p36 while the 3q26-27 region harbors miR-15b, miR-
16-2 and other microRNAs including miR-1263, miR-720, miR-
551b, miR-569, miR-1224. We also found that additional
members of the oncogenic miR15/16 family (miR-15a and
miR-16) as well as the members of the miR-17-92 polycistron
were lost with the 13q12.12-q33.2 region of a single patient B4
(Table 3).
Candidate role of the loss of miR-200 family and miR-15
and miR16 in ULMs
Loss of miR-200 family is associated with epithelial and
mesenchymal transition (EMT) and aggressive tumor phenotypes of
ovarian cancer [30,31]. We observed that miR-200a and miR-200b
were significantly down regulated in 51 ULMs (net loss of
20.3660.11 and 20.4560.06, respectively). To further explore
the potential significance of the deletion overlap involving the miR-
200family,weexamined gene expressionin patientsand found that a
number of TargetScan-predicted targets of either miR-200a or miR-
200b were collectively upregulated in the tumor compared to
unaffected pair-matched myometrium (,180 genes ranging from
1.25–10.3 fold upregulation). Among these were genes with
established roles in cancer and cell death regulation: MAF (v-maf
musculoaponeurotic fibrosarcoma oncogene), CTBP2 (C-terminal
binding protein 2), antiapoptotic BCL2 (B-cell CLL/lymphoma 2),
CITED2 (Cbp/p300-interacting transactivator), LASS6 (LAG1
homolog, ceramide synthase 6), PHF21A (PHD finger protein
21A), TSC22D1 (TSC22 domain family, member 1), ATXN1
(ataxin 1), JUN (jun oncogene) and NFIB (nuclear factor I/B).
Focused pathway analysis (using GO, KEGG, Biocarta and Panther
databases) of the predicted miR-200 family targets that are
consistently upmodulated in ULMs including patient B4 (Table S3)
implicates categories of regulation of transcription proliferation and
Figure 3. MiR-200 predicted target gene analysis in uterine ULMs. A Scatter plot analysis of relative mRNA expression in five miR-200
predicted target genes in 10 ULMs and matched myometria (our data and GSE593). Red bars indicate the mean and standard error of measurement.
B RT-PCR analysis of expression of five miR-200 predicted target genes in ULMs cell line UtLM with stable miR-200a expression (see Methods) and
control (vector PGIPZ only). Repression of TUBB, CYP1B1 and CTBP2 can be readily appreciated. C Growth curves illustrate significantly reduced
proliferative rate in UtLM cell line with miR-200a overexpression in comparison UtLM cell line with vector control only (PGPIZ). D. Photomicrographs
illustrate stable viral control (upper panels) and miR-200a (lower panels) expression in UtLM cell lines. The stromal to epithelial morphology transition
in UtLM cell line with miR-200a overexpression is evident (lower panels).
doi:10.1371/journal.pone.0012362.g003
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focaladhesionjunctionremodeling,aswellascancerrelatedsignaling
pathways (MAPK, RAS, WNT, NOTCH, TGF-b,V E G F ) .
Similarly, loss of miR-15/miR-16 cluster is associated with
aggressive tumor growth [32]. The findings indicated alteration of
these two genomic regions may be related to the tumorigenesis of
ULMs. We have evaluated the expression levels of TargetScan
predicted mRNA targets and found that important transcriptional,
signaling and other regulators of cell growth and survival linked to
cancer were also collectively upmodulated in patient B4, among
them FOXO1A (forkhead box O1A (rhabdomyosarcoma)), BCL2
(B-cell CLL/lymphoma 2), TGFBR3 (transforming growth factor,
beta receptor III (betaglycan, 300kDa)), MAP3K4 (mitogen-
activatedprotein kinasekinase kinase 4),VEGF(vascularendothelial
growth factor), TCF3 (transcription factor 3), EIF4E (eukaryotic
translation initiation factor 4E), JARID2 (Jumonji, AT rich
interactive domain 2), EVI5 (ecotropic viral integration site 5),
IGF1 (insulin-like growth factor 1), WNT5B (wingless-type MMTV
integrationsitefamily, member 5B).Detailed pathway analysis ofthe
upregulated targets of the lost miR-15/16 family identified biological
categories of pathways in cancer, endometrial cancer, transcription,
melanoma, apoptosis, signaling pathways including insulin, MAPK,
mTOR, VEGF, ErbB, JAK/STAT signaling, and cell-cell adhesion
and cytoskeleton remodeling (see Supplemental Table 3)
We also identified a subset of upregulated genes that are
predicted as targets of both miR-200a/b and miR-15/16 micro-
RNAs from the regions of deletion overlap on Chr1 and Chr3
(Table 3), including ACTR1A, BACH2, BCL2, CDC14B,
CLASP1, CYP26B1, E2F3, EVI5, FUBP1, IKBKB, IRS2,
IRS2, LRIG1, OTUD4, PCDH9, PCDH9, PELI2, PHF21A,
PPAP2B, SLC2A3, SNTB2, TMCC1 and TUBB.
These findings indicated that alteration (loss) of two overlapping
genomic regions (7.09 Mb of Chr1 1p36.33-p36.23 and 24.56 Mb
of Chr3 3q26.1-q27.2 harboring cancer related miRNAs may be
related to the tumorigenesis of a subset of ULMs via deregulation
of the miR200a/b and miR-15/16 gene targets and in part this
process may be due to the loss of convergent inhibitory action of
the miR-200 family and miR-15 and miR-16 on a small group of the
same downstream target genes.
Functional correlation of microRNAs and mRNA
expression in cultured leiomyoma cell lin
As shown above, downregulation of miR-200 family members
appears a candidate event in leiomyomas in select patients due to
loss of corresponding genomic DNA loci and broader reduction of
miR-200 expression in ULMs (Table 3 and Figure S2). We selected
5 target genes of miR-200a that were all significantly upregulated
in ULMs (Figure 3A) for functional testing as direct targets and for
their roles in cell phenotype changes. In the UtLM cell line with
stable miR-200a overexpression, 3 of 5 mRNAs (TUBB, CYP1B1
and CTBP2 were suppressed by miR-200a in vitro (Figure 3B).
Importantly and as predicted by pathway analysis (Table S3),
overexpression of miR-200a in UtLM cells led to growth inhibition
compared to mock infected controls (Figure 3C), and reverted the
fibroblastoid morphology towards more pronounced epithelial
phenotype (Figure 3D), consistent with the established role of miR-
200 family in epithelial-mesenchymal transition [33]. Collectively,
these findings suggest that the loss of miR-200 family, identified by
Figure 4. Analysis of the miR-296 predicted target gene TSC2 and 11 let-7 predicted target genes in vitro.ATransient transfection
analysis for luciferase reporter expression with TSC2 39UTR in the presence and absence of miR-296. B Immunoblotting analysis of transient
transfection analysis of miR-296 for TSC2 expression. TSC2 siRNA was used as a positive control antagonizing TSC2 expression. Block-
iT=nonfucntional small RNA control. b-Actin was used as protein loading control. C Relative expression of let-7 predicted target genes (listed above)
(y-axis) in transient transfection of nonfunctional small RNA (Block-iT (Controls), let-7c mimic and let-7 inhibitor (Anti-let-7). The relative expression
levels were obtained in three cell lines of immortalized ULM cell line (ULM-3401), leiomyosarcoma cell lines (LMS-1, UT-1) (see Methods). T-bars
indicate standard error of measurement. *=p value,0.05.
doi:10.1371/journal.pone.0012362.g004
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of its target genes may contribute to the tumor growth and
underlie the mesenchymal character of ULMs.
We previously found that the product of TSC2 gene (tuberin)
was significantly down regulated in ULMs [27,34]. Downregula-
tion of TSC2 was also found in this study (Figure S3). By
correlation analysis, as illustrated in Figure 2, we found that
predicted regulatory miR-296 was inversely correlated with TSC2
protein in 36 ULMs. TSC2 contains 41 exons with a very short 39
untranslated region (39UTR, ,110 nt). The short TSC2 39UTR
may prevent microRNA regulation. However, in the TSC2
39UTR immediately adjacent to the stop codon, there is a highly
conserved sequence that harbors the complementary sites of miR-
296 and a few other microRNAs. To study whether TSC2 is the
target of miR-296, we prepared a TSC2 39UTR reporter construct
and examined the luciferase activity by treated cells with control,
miR-296 mimic and inhibitor. There was no reduction of luciferase
expression in cell treated with miR-296 (Figure 4A). We further
examined whether miR-296 could inhibit TSC2 protein produc-
tion. In comparison to TSC2 siRNA, no significant protein
reduction was noted in cells treated with miR-296 (Figure 4B). The
findings indicated that TSC2 was not a direct target of miR-296.
The inverse correlation of TSC and miR-296 levels may thus be
related to indirect or unrelated molecular mechanisms participat-
ing in ULM tumorigenesis.
We had reported that most members of the let-7 family were
dysregulated in ULMs [13]. To test whether let-7 microRNAs
could regulate other predicted target genes in addition to HMGA2
in ULMs, we examined the expression of several predicted let-7
target genes in the ectopically induced presence or absence of let-7
microRNAs in uterine ULMs and leiomyosarcoma cell lines in
vitro. TargetScan and PicTar databases [35,36] predicted 65 target
genes of let-7 mRNAs that are significantly dysregulated in ULMs
(Figure 1B1), of which 45 (69%) were downregulated. Of those, we
selected 11 candidate targets involved in cell proliferation and
extracellular matrix regulation that might be functionally associ-
ated with the pathogenesis of ULMs. By transient transfection and
RT-PCR analysis (Table S1), we found that 6 of them can be
repressed by let-7s (Figure 4C). Thus our findings indicate that a
subset of the predicted target genes can be significantly repressed
in experimental conditions. Importantly, this set of experiments
indicates that follow-up biochemical functional studies are
warranted to validate the prediction- and inverse correlation-
based analyses of individual microRNA::mRNA relationships.
Interpretation of focused miRNA::mRNA relationship
compared to genome wide pathway analysis
We asked whether inverse correlation of the top 5 up- and
down-regulated miRNA profiles with their target genes is
sufficiently representative to identify top categories in comparison
to broad data mining of the ULM mRNA profiles. To that end, we
performed gene set enrichment analysis (GSEA, Figure 5) using
the combined expression data from our and the GSE593 data and
compared the results of top categories with the DAVID analysis of
pooled 346 top miRNA targets (Fig 1B) presented in Table 4. A
number of themes showed overlap, such as cell cycle and DNA
replication control, proliferation control indicated by pathways
such as MAPK, JAK/STAT, developmental signaling (WNT,
Figure 5. Gene Set Enrichment Analysis (GSEA) of mRNA profiling results from primary ULMs and matched myometria. The
histograms show the distribution of select top GSEA molecular signatures from predefined C2 and C5 categories (accessible from the MolSig
database at http://www.broadinstitute.org/gsea/msigdb/index.jsp). The leading edge (most significant genes) are shown as vertical bars accumulated
either left and below the peak of green enrichment score plot (A) or right of the valley of the green plot (B), indicating the respective up- or down-
regulated genes of each shown GSEA characterized by the highest enrichment score. C The leading edge (genes with the highest enrichment score)
of the EMT-down category (shown in B) is shown as individual gene expression-based heat map and indicates downregulation of the TGF-b signal
and of its canonical targets in ULMs.
doi:10.1371/journal.pone.0012362.g005
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morphological and migratory properties of the tumors (cell-cell
junction, cell adhesion and cytoskeleton remodeling) found in
miRNA target analysis are complemented by MET, WNT and
TGF-b signaling, major regulators of invasion and motility, found
in both types of analysis. We thus propose that the reduced
information contents resulting from functional interpretation of
the relationships between a limited number of top regulated
miRNAs and their inversely correlated mRNA targets sufficiently
identifies key functional themes, with results comparable to the
global, genome-wide mRNA analysis.
Discussion
Although it has been shown that individual microRNAs may
regulate multiple genes, the current knowledge for micro-
RNA::mRNA regulation has been largely obtained from the
studies of the disruption of microRNA::mRNA interactions on a
single gene basis. Recently, several attempts to examine
microRNA::mRNA interactions globally have been pursued
[37,38,39]. In our previous study of TGF-b-directed epithelial
to mesenchymal transition, we explored a global approach to
study the dynamics of microRNA::mRNA interactions [40]. The
application of this genome-wide analysis of microRNA::mRNA
expression in ULMs allows us to gain insight into the role of
microRNAs in the regulation specific mRNAs and their protein
products. In a correlation analysis between dysregulated mRNAs
and the most highly of dysregulated microRNAs in ULMs, an
overall negative correlation was established (Table 2 and Table
S1, Figure 1).
Among many dysregulated microRNAs and target genes in
leiomyomas, correlation of HMGA2 and the let-7 family has been
well characterized [13,17,18,19] and shown as biologically
significant for leiomyoma growth [13,41]. We expected to see
broader dysregulation of additional genes in uterine leiomyomas
due to regulation by specific microRNAs. In the selected predicted
targets which we examined at the mRNA and protein levels, we
found that some, but not all of them, appear to be regulated by
microRNAs (Figures 2, 3, and 4). Our findings further support the
notion that the selection of the predicted microRNA targets relies
on the rank (strength) of the target prediction scores (Table S1) and
that the functional regulation relies on the level of microRNA
expression in the cell and convergent, synergistic effects of multiple
microRNAs on one target gene. Varying functional validation
outcomes of multiple genes tested as miRNA targets (Figures 3B
and 4) importantly demonstrate the complexity of target gene
regulation by microRNAs and indicate the need for detailed
validation in prediction- and inverse correlation-based studies.
Uterine ULMs are the most common benign neoplasms,
exhibiting complex patterns of gene dysregulation [1,2]. The
dysregulated genes are involved in many cellular and molecular
functions, such as defects in angiogenesis [42], nuclear receptors
and local growth factors [2], dysfunction of extracellular matrix
[43] and TGF-b signaling [44]. The molecular mechanisms
leading to the dysregulation of these genes has been largely
unknown. As illustrated in Table 4, several tumorigenic pathways
seem to be regulated by the most highly dysregulated microRNAs
in ULMs. For example, at least nine predicted target genes of
upregulated microRNAs in the Mitogen-activated protein kinase
(MAPK) signaling pathway were downregulated. This finding was
validated by the GSEA analysis of mRNA expression data
(Figure 5B). MAPK signaling has been shown to play a significant
role in tumorigenesis by controlling tumor growth, proliferation,
differentiation, migration and apoptosis [45]. Activation of MAPK
Table 4. KEGG/Biocarta analysis of functions of predicted target genes of miRNAs in ULM.
PATHWAY miRNAs: Up Down Gene Symbols
mRNAs: Down Up
MAPK SIGNALING ACVR1B, MEF2C 9 RPS6KA3, DUSP1, PDGFRB, RRAS2, MAPK14, MAP3K5,
FOCAL ADHESION GAP JUNCTION 7 MET, CCND2, TNXB, PDGFRB, RRAS2, ITGB3, CVR1B
REGULATION OF ACTIN CYTOSKELETON 6 ADCY9, ADCY3, CSNK1A1, GJA1, PDGFRB, RRAS2,
CYTOKINE-CYTOKINE 6 RDX, MYH9, PDGFRB, RRAS2, ARHGEF6, ITGB3,
RECEPTOR INTERACTION 5 MET, CSF1, KITLG, PDGFRB, ACVR1B,
ECM-RECEPTOR INTERACTION 5 TNXB, ITGB3, DTPRECK, TIMP3,
CELL CYCLE 5 CCND2, CCNH, RB1, ABL1, KITLG,
CALCIUM SIGNALING 4 ADCY9, ADCY3, PDGFRB, EDNRB,
JAK-STAT SIGNALING 4 SPRY1, STAT3, CCND2, STAT5B,
NFAT AND HYPERTROPHY OF THE HEART 4 CSNK1A1, MAPK14, HBEGF, MEF2C,
PPARa ´ SIGNALING 3 RB1, DUSP1,STAT5B,
NFkB ACTIVATION 3 NR3C1,DUSP1,MAPK14,
TGF-a ˆ SIGNALING 3 CHRD, ACVR1B, SMAD7,
ADHERENS JUNCTION 2 MET, ACVR1B,
TIGHT JUNCTION 2 MYH9, RRAS2,
WNT SIGNALING 2 CCND2, CSNK1A1,
CELL ADHESION 3 NCAM1, CDH2, IGSF4,
INSULIN SIGNALING 3 SOCS2, PPARGC1A, FOXO3A,
CYTOKINE-CYTOKINE RECEPTOR INTERACTION 2 CXCL12, PDGFC,
FOCAL ADHESION 2 COL2A1, PDGFC,
doi:10.1371/journal.pone.0012362.t004
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tumors to gain the capability of independent growth, insensitivity
to anti-growth signals, unlimited replicative potential and the
ability to invade and metastasize [45]. ULMs are relatively slow
growing smooth muscle tumors and rarely, if ever, progress to
malignancy. Repression of MAPK pathway genes by microRNAs
in ULMs may represent a protective mechanism from fast growth
and potential tumor progression.
Downregulation of many target genes of upregulated micro-
RNAs including genes involved in focal adhesion (seven), gap
junction (six), actin cytoskeleton (six) and extracellular matrix
formation (five) have been identified (Table 4). These categories
are related to cell remodeling, migration, growth and tumor
progression [2,43]. Thus, certain upregulated microRNAs may
prevent aggressive tumor growth through repression of the target
genes that are responsible for tumor cell communication and
extracellular matrix formation and may in part play a protective
role in avoiding aggressive behavior of ULMs. Conversely, loss of
miR-200 shown to modulate growth as well as the UtLM
morphology (Figure 4C,D), may lead to upregulation of genes
(some of them convergent targets of lost miR-15/16) that
contribute to the progression of ULM tumorigenesis.
Key components of the TGF-b and of MET signaling pathways
are downmodulated in ULMs (Figure 5B and Table 4), both
having a role in cell growth control, tumor progression, and
oncogenic effects associated with invasive growth and extracellular
matrix remodeling [44,46]. Despite the downregulation of
established TGF-b targets CTGF and THBS1 in ULMs (see
Figure 5C, listing significant genes from EMT down category in
Fig 5B), future studies will be required to determine whether
microRNAs participate in TGF-b-mediated regulation of the
profibrogenic extracellular matrix deposition in ULMs.
In conclusion, our global correlation analysis of gene product
levels and microRNA expression provide a comprehensive and
biologically meaningful insight into tumorigenesis of ULMs. This
is documented by the relationship between the five most highly
overexpressed microRNAs and a downregulated group of target
genes that are related to cellular structure, extracellular matrix and
cell proliferation, a signature that can be related to the slow growth
and non aggressive behavior of uterine ULMs.
Supporting Information
Figure S1 MicroRNA and mRNA expression profiles in five
large uterine leiomyomas. microRNA and mRNA expression
profiles in five large uterine leiomyomas from black women
(Table 1). A. Unsupervised hierarchical clustering (HCL) of 206
human microRNAs in 5 large ULMs (.10 cm) normalized to the
matched myometria is shown. B. HCL illustrating a concordance
of total of 2674 significantly dysregulated genes between 5 ULMs
from this study (left panel) and the NCBI GEO GSE593 data
set (right panel), normalized to matched myometria. yellow=
upregulation; blue=downregulation.
Found at: doi:10.1371/journal.pone.0012362.s001 (0.69 MB JPG)
Figure S2 Regions of common loss in ULMs detected by array
CGH. A, B. Genome browser mapping of the regions of common
loss of genomic material as detected by a CGH in this study.
Patient IDs are shown as yellow rectangles. Cancer-related
microRNAs of interest in the deleted regions are listed under the
chromosomes and highlighted by red arrowheads. C. Detailed
genetic summary of the common regions of loss.
Found at: doi:10.1371/journal.pone.0012362.s002 (0.60 MB JPG)
Figure S3 TMA immunohistochemical analysis of selected
proteins in ULMs. Immunohistochemical analysis of selected
proteins in 36 ULMs. A. Photomicrograph illustrating tissue
microarray (TMA) sections with hematoxylin and eosin (H&E)
stain (upper panel) and immunostaining of ER (bottom panel).
Triplicate tissue cores from controls (matched myometrium) and
tumors (ULMs) are indicated on the right. B. Differential
expression of the selected target gene products is shown as mean
and standard error of measurements (bars and t-bars, respectively).
The net change for each gene product was calculated based on
relative immunoreactivity in ULMs against matched myometrium.
Red=gain in protein levels; Blue=reduction of protein levels.
Found at: doi:10.1371/journal.pone.0012362.s003 (0.61 MB JPG)
Table S1 Primers and PCR results for the predicted target genes
of let-7 and miR-200s.
Found at: doi:10.1371/journal.pone.0012362.s004 (0.03 MB
DOC)
Table S2 Antibodies used in this study.
Found at: doi:10.1371/journal.pone.0012362.s005 (0.03 MB
DOC)
Table S3 Predicted target genes and pathways downstream of
miR-200s amd miR-15/16.
Found at: doi:10.1371/journal.pone.0012362.s006 (0.81 MB
DOC)
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